المؤلفون: Robert J. Padley, Claude Schulman, Jennifer L. Schmitt, Jürgen Breul, Mark A. Weinberg, Joel B. Nelson, Azmi A. Nabulsi, Michael A. Carducci, Rod A. Humerickhouse, Danai D. Daliani, Nicholas J. Vogelzang, Bernard A. Zonnenberg

المصدر: Journal of Clinical Oncology. 21:679-689

مصطلحات موضوعية: Endothelin Receptor Antagonists, Male, Cancer Research, medicine.medical_specialty, Pyrrolidines, Acid Phosphatase, Urology, Placebo-controlled study, Antineoplastic Agents, Adenocarcinoma, Placebo, law.invention, Prostate cancer, chemistry.chemical_compound, Randomized controlled trial, law, Clinical endpoint, medicine, Humans, Aged, Dose-Response Relationship, Drug, L-Lactate Dehydrogenase, Zibotentan, business.industry, Atrasentan, Prostatic Neoplasms, Receptor, Endothelin A, medicine.disease, Surgery, Treatment Outcome, Oncology, chemistry, Tumor progression, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b8cb9c55105549b0d0ddc7bb324f662
https://doi.org/10.1200/jco.2003.04.176